Ventilator Associated Pneumonia, Antibiotic Resistant Infection
Conditions
Brief summary
The aim of this study is to report our experience with ceftolozane-tazobactam and to evaluate its safety and efficacy in the treatment of ICU dependent nosocomial respiratory tract infections due to extensively drug resistant Pseudomonas aeruginosa. Different dosing regimes of ceftalozane-tazobactam is evaluated and compared to the standard therapy of Colomycin.
Detailed description
Ceftolozane-tazobactam (C/T) is a novel type of beta-lactam/beta-lactamase inhibitor antibiotics targeting nosocomial infections caused by Gram-negative bacteria. In recent years, ceftolozane-tazobactam was prescribed for treating complicated urinary tract infections (cUTI) and complicated intraabdominal infections (cIAI). Following the results of ASPECT-NP trial in 2019, it was approved as a therapeutic option in nosocomial pneumonia including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). The drug shows an excellent activity against ESBL-producing Enterobacterales and multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Pseudomonas aeruginosa. The latter is widely recognized as a common pathogen of nosocomial respiratory tract infections. There is still a need for observations of clinical experiences to better define the risk-benefit profile of ceftolozane-tazobactam. The aim of this study is to report our experience with ceftolozane-tazobactam and to evaluate its safety and efficacy in the treatment of ICU dependent nosocomial respiratory tract infections due to extensively drug resistant Pseudomonas aeruginosa. Different dosing regimes of ceftalozane-tazobactam is evaluated and compared to the standard therapy of Colomycin.
Interventions
Administration
Sponsors
Semmelweis University
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to 90 Years
Inclusion criteria
* Hospital-acquired pneumonia caused by extensively drug-resistant Pseudomonas aeruginosa * ≥ 72 hours of targeted antibiotic therapy against Pseudomonas aeruginosa with either Colomycin or Ceftolozane-Tazobactam
Exclusion criteria
* Participation in an interventional trial aiming nosocomial infections * Treatment was not with the intent to cure the infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical cure rate | 7-14 day |
| Microbiological cure rate | 7-14 day |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| LOS | 28 | Lenght of ICU stay |
| Length of ventilation | Untill patient is ventilated (expected time frame is 10 days) | — |
| 28 day mortality | 28 | — |
| Drug related adverse events rate | until ICU discharge (expected average day is 14) | The number and nature |
Countries
Hungary
Outcome results
None listed